157 related articles for article (PubMed ID: 23762842)
1. Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Pilz LR; Strauss LG; Sachpekidis C; Hohenberger P
Biomed Res Int; 2013; 2013():389672. PubMed ID: 23762842
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Strauss LG; Hohenberger P
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1876-82. PubMed ID: 20559633
[TBL] [Abstract][Full Text] [Related]
3. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
4. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
5. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
6. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
7. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Jager PL; Gietema JA; van der Graaf WT
Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
[TBL] [Abstract][Full Text] [Related]
9. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
10. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
13. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Zincirkeser S; Sevinc A; Kalender ME; Camci C
World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
[TBL] [Abstract][Full Text] [Related]
14. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Kasper B; Schmitt T; Wuchter P; Dimitrakopoulou-Strauss A; Ho AD; Egerer G
Mar Drugs; 2009 Jul; 7(3):331-40. PubMed ID: 19841717
[TBL] [Abstract][Full Text] [Related]
15. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
[TBL] [Abstract][Full Text] [Related]
16. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
[TBL] [Abstract][Full Text] [Related]
17. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
18. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
[TBL] [Abstract][Full Text] [Related]
19. Esophageal gastrointestinal stromal tumor: report of 7 patients.
Shinagare AB; Zukotynski KA; Krajewski KM; Jagannathan JP; Butrynski J; Hornick JL; Ramaiya NH
Cancer Imaging; 2012 Apr; 12(1):100-8. PubMed ID: 22542728
[TBL] [Abstract][Full Text] [Related]
20. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
